These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33859517)

  • 1. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
    Deng L; He K; Pan Y; Wang H; Luo Y; Xia Q
    Int J Med Sci; 2021; 18(10):2109-2116. PubMed ID: 33859517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β,β-Dimethylacrylalkannin, a Natural Naphthoquinone, Inhibits the Growth of Hepatocellular Carcinoma Cells by Modulating Tumor-Associated Macrophages.
    Shen LS; Lin Z; Gong RH; Lin YS; Qiao XF; Hu QM; Qin WH; Chen S; Yang Y; Chen GQ
    Molecules; 2024 Aug; 29(16):. PubMed ID: 39202998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophages as Targets in Hepatocellular Carcinoma Therapy.
    Liu YT; Mao ZW; Ding Y; Wang WL
    Mol Cancer Ther; 2024 Jun; 23(6):780-790. PubMed ID: 38310642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
    Song JS; Chang CC; Wu CH; Dinh TK; Jan JJ; Huang KW; Chou MC; Shiue TY; Yeh KC; Ke YY; Yeh TK; Ta YN; Lee CJ; Huang JK; Sung YC; Shia KS; Chen Y
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
    Xia Y; Brown ZJ; Huang H; Tsung A
    Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy.
    Zhang Y; Han G; Gu J; Chen Z; Wu J
    Front Immunol; 2024; 15():1429812. PubMed ID: 39170620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
    Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
    Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression.
    Sun P; Li Z; Yan Z; Wang Z; Zheng P; Wang M; Chang X; Liu Z; Zhang J; Wu H; Shao W; Xue D; Yu J
    BMC Cancer; 2024 Jul; 24(1):922. PubMed ID: 39080642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: Characterization and treatment (Review).
    Yu M; Yu H; Wang H; Xu X; Sun Z; Chen W; Yu M; Liu C; Jiang M; Zhang X
    Int J Oncol; 2024 Oct; 65(4):. PubMed ID: 39239752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization.
    Chen M; Lai R; Lin X; Chen W; Wu H; Zheng Q
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy.
    Helal IM; Kamal MA; Abd El-Aziz MK; El Tayebi HM
    Expert Rev Mol Med; 2024 Sep; 26():e18. PubMed ID: 39320855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research progress on tumour‑associated macrophages in gastric cancer (Review).
    Zhou Z; Yang Z; Wang J; Wang Q; Zhang H; Ju X
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8
    Zhu CX; Yan K; Chen L; Huang RR; Bian ZH; Wei HR; Gu XM; Zhao YY; Liu MC; Suo CX; Li ZK; Yang ZY; Lu MQ; Hua XF; Li L; Zhao ZB; Sun LC; Zhang HF; Gao P; Lian ZX
    J Hepatol; 2024 Oct; 81(4):690-703. PubMed ID: 38759889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.